文献速递慢性肾脏病水电解质与酸碱

拟钙剂在尿毒症大鼠中维持骨转换 despite PTH下降

Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.
PubMed 文献 · Kidney Int · 2019-03-12

本研究在甲状旁腺切除后持续输注PTH的大鼠模型中,评估拟钙剂AMG 641对骨细胞的直接作用。结果显示拟钙剂在正常和尿毒症大鼠中增加成骨细胞数量和骨形成,且在体外促进成骨分化与矿化,提示其具有不依赖PTH降低的直接骨合成效应。

要点

  • 拟钙剂在PTH钳制下仍增加正常大鼠成骨细胞数量和类骨质体积。
  • 尿毒症大鼠中拟钙剂降低血浆PTH但增加成骨细胞数量、类骨质表面和骨形成。
  • 体外拟钙剂激活CaSR诱导Erk1/2磷酸化和成骨基因表达,促进人骨髓间充质干细胞成骨分化与矿化。

核心结论

  • 拟钙剂对骨具有直接合成代谢效应,可抵消PTH水平下降带来的骨转换降低。

研究设计与样本

  • 研究采用体外细胞实验与体内大鼠模型,包括正常和5/6肾切除诱导的尿毒症大鼠,行甲状旁腺切除后持续皮下输注PTH以钳制PTH水平,并给予拟钙剂AMG 641或溶媒。

主要发现

  • 在PTH钳制的正常大鼠中,拟钙剂增加成骨细胞数量和类骨质体积。
  • 在尿毒症大鼠中,高PTH导致骨体积减少和骨转换增加,拟钙剂降低血浆PTH。
  • 在接受6倍常规替代剂量PTH的尿毒症大鼠中,拟钙剂增加成骨细胞数量、类骨质表面和骨形成。
  • 在9倍更高剂量PTH导致骨转换增加的大鼠中,拟钙剂未改变骨转换。
  • 体外拟钙剂诱导骨肉瘤细胞系Erk1/2磷酸化和成骨基因表达,而拟钙剂拮抗剂产生相反效应;拟钙剂促进人骨髓间充质干细胞成骨分化和矿化。

临床怎么用

  • 拟钙剂在降低PTH的同时可能维持或增加骨形成,临床需关注其对骨转换的直接作用。

局限性

  • 研究为大鼠模型和体外实验,人体中的直接骨效应需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calcimimetics decrease parathyroid hormone (PTH) secretion in patients with secondary hyperparathyroidism. The decrease in PTH should cause a reduction in bone turnover; however, the direct effect of calcimimetics on bone cells, which express the calcium-sensing receptor (CaSR), has not been defined. In this study, we evaluated the direct bone effects of CaSR activation by a calcimimetic (AMG 641) in vitro and in vivo. To create a PTH "clamp," total parathyroidectomy was performed in rats with and without uremia induced by 5/6 nephrectomy, followed by a continuous subcutaneous infusion of PTH. Animals were then treated with either the calcimimetic or vehicle. Calcimimetic administration increased osteoblast number and osteoid volume in normal rats under a PTH clamp. In uremic rats, the elevated PTH concentration led to reduced bone volume and increased bone turnover, and calcimimetic administration decreased plasma PTH. In uremic rats exposed to PTH at 6-fold the usual replacement dose, calcimimetic administration increased osteoblast number, osteoid surface, and bone formation. A 9-fold higher dose of PTH caused an increase in bone turnover that was not altered by the administration of calcimimetic. In an osteosarcoma cell line, the calcimimetic induced Erk1/2 phosphorylation and the expression of osteoblast genes. The addition of a calcilytic resulted in the opposite effect. Moreover, the calcimimetic promoted the osteogenic differentiation and mineralization of human bone marrow mesenchymal stem cells in vitro. Thus, calcimimetic administration has a direct anabolic effect on bone that counteracts the decrease in PTH levels.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Díaz-Tocados JM, Rodríguez-Ortiz ME, Almadén Y, et al. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int. 2019. PMID: 30878213. doi:10.1016/j.kint.2018.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。